Pulse wave transit time during exercise testing reflects the severity of heart disease in cardiac patients

Yuta Takayanagi¹, Akira Koike², Hiroshi Kubota³, Longmei Wu³, Isao Nishi⁴, Akira Sato³, Kazutaka Aonuma³, Yasushi Kawakami¹, Masaki Ieda³

¹Department of Clinical Laboratory, University of Tsukuba Hospital, Tsukuba, Japan; ²Medical Science, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; ³Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; ⁴Master’s Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; ⁵Department of Cardiology, Kamisu Clinical Education and Training Center, University of Tsukuba, Kamisu, Japan.

SUMMARY  The pulse wave transit time (PWTT) is easily measured as the time from the R wave of an electrocardiogram to the arrival of the pulse wave measured by an oxygen saturation monitor at the earlobe. We investigated whether the change of PWTT during exercise testing reflects cardiopulmonary function. Eighty-nine cardiac patients who underwent cardiopulmonary exercise testing (CPX) were enrolled. We analyzed the change of PWTT during exercise and the relationship between the shortening of the PWTT and CPX parameters. PWTT was significantly shortened from rest to peak exercise (204.6 ± 33.6 vs. 145.6 ± 26.4 msec, p < 0.001) in all of the subjects. The patients with heart failure had significantly higher PWTT at peak exercise than the patients without heart failure (152.7 ± 27.1 vs. 140.4 ± 24.8 msec, p = 0.031). The shortening of PWTT from rest to peak exercise showed significant positive correlations with the peak O₂ uptake (VO₂) (r = 0.56, p < 0.001), anaerobic threshold (r = 0.40, p = 0.016), and % increase of systolic blood pressure during exercise (r = 0.75, p < 0.001), and a negative correlation with the slope of the increase in ventilation versus the increase in CO₂ output (VE-VCO₂ slope) (r = −0.42, p = 0.010) in the patients with heart failure. PWTT was shortened during exercise as the exercise intensity increased. In the patients with heart failure, the shortening of PWTT from rest to peak exercise was smaller in those with lower exercise capacity and those with higher VE-VCO₂ slope, an established index known to reflect the severity of heart failure.

Keywords  Pulse wave transit time, exercise testing, cardiopulmonary function

1. Introduction

The pulse wave transit time (PWTT) is the time from the electrocardiogram R wave to the arrival of the pulse wave measured by an oxygen saturation monitor at the earlobe. PWTT is thought to be at least partly related to cardiovascular function, as it has been reported to shorten when the blood pressure rises (1,2). As a parameter that can be easily and continuously measured, PWTT has the potential to serve as a useful clinical tool for identifying changes in cardiovascular function, especially during exercise. Little is known, however, about the change of PWTT during exercise or the relation of that change to cardiopulmonary function.

Cardiopulmonary exercise testing (CPX) is one of the most useful clinical tools for evaluating the severity of disease and the limitations of physical activities in cardiac patients (3). Among the parameters obtained from CPX, the peak oxygen uptake (VO₂) noninvasively reflects maximal cardiac output during exercise and is accordingly considered a strong prognostic factor and gold standard for selecting patients for cardiac transplantation (4,5). The slope of the increase in ventilation (VE) versus the increase in CO₂ output (VE-VCO₂ slope) during exercise is another important parameter for evaluating the severity of heart failure (6).

In the present study we compared PWTT at rest, at anaerobic threshold (AT), and at peak exercise between patients with and without heart failure. We also evaluated the relation of the change of PWTT during exercise with the established CPX indices.
2. Methods

2.1. Study subjects

This is the retrospective study. The subjects for this study were 103 consecutive cardiac patients who underwent CPX for evaluation of exercise capacity and/or severity of cardiac disease at the University of Tsukuba Hospital between March 2017 and April 2018. Fourteen of the subjects were excluded because the PWTT at peak exercise could not be measured. In total, 89 subjects were selected (Table 1). The etiologies of heart disease in the cardiac patients were valvular heart disease in 28 patients, congenital heart disease in 25, coronary artery disease in 19, idiopathic dilated cardiomyopathy in 6, arrhythmia in 5, and other cardiac disease in 6. Thirty-eight of the patients had heart failure categorized as New York Heart Association class II or III. The protocol was approved by the Institutional Review Board of the University of Tsukuba Hospital. All of the subjects gave their informed consent to perform CPX.

2.2. Exercise testing and respiratory gas analysis

An incremental symptom limited exercise test was performed using an upright, electromagnetically braked cycle ergometer (Strength Ergo 8; Mitsubishi Electric Engineering Co., Ltd., Tokyo, Japan). The exercise test began with 4 minutes of rest on the ergometer followed by 4 minutes of warm-up at 0 or 20 W at 50 rpm. The load was then increased by 1 W every 6 seconds (10 W/min).

\[ \text{VO}_2, \text{VCO}_2, \text{and VE were measured throughout the test using an Aeromonitor AE-300s (Minato Medical Science, Osaka, Japan). The Aeromonitor AE-300s consists of a microcomputer, a hot wire flowmeter, and a gas analyzer composed of a sampling tube, filter, suction pump, infrared CO}_2 \text{ analyzer, and O}_2 \text{ analyzer equipped with a paramagnetic oxygen cell. The VO}_2 \text{ and VCO}_2 \text{ were calculated breath-by-breath based on the mathematical analysis described by Beaver et al. (7). The time alignment between the concentration and flow was performed based on the time delays of the O}_2 \text{ and CO}_2 \text{ analyzers (the flow delay from the sampling site to the analyzer plus the response time of the analyzer) (8). Before the parameters from the respiratory gas analysis were calculated, the breath-by-breath data were interpolated to give second-by-second values. These second-by-second values were then calculated as successive 3-second averages, and the averages were translated into a 5-point moving average.} \]

The peak VO\(_2\) was calculated as the average of the values obtained during the last 15 seconds of incremental exercise. The percentage of peak VO\(_2\) was calculated by dividing the measured peak VO\(_2\) by the predicted peak VO\(_2\). The predicted peak VO\(_2\) was determined on the basis of a normal Japanese population (9). The VE-VCO\(_2\) slope during incremental exercise was calculated from the start of incremental exercise to the respiratory compensation point by least-squares linear regression, as previously described (5). The AT was determined by V-slope analysis (10). The ratio of the increase in VO\(_2\) to the increase in the work rate (\(\Delta\text{VO}_2/\Delta\text{WR}\)) was calculated by least-squares linear regression from the data recorded from 30 seconds after the start of incremental exercise to 30 seconds before the end of exercise (5).

2.3. Analysis of the PWTT

Figure 1 demonstrates the measurement of PWTT. PWTT was measured using an electrocardiograph (STS 2100; NIHON KOHDEN, Tokyo, Japan) and oxygen saturation monitor attached to the earlobe. PWTT was defined as the interval from the R wave of the electrocardiogram to the arrival of the pulse wave measured by an oxygen saturation monitor at the earlobe. PWTT was continuously measured from rest to the end of the exercise test as the average of the previous 64 beats, and sampled every 15 seconds. The shortening of PWTT was expressed as a percentage of the decrease in PWTT at peak exercise versus that at rest.

2.4. Statistical analysis

Data are presented as the mean ± S.D. Intergroup differences for variables were compared by the unpaired t test or the Fisher’s exact test where appropriate. The linear regression analysis was used to correlate the measured variables. All analyses were performed using SPSS version 22.0 software (SPSS Inc., Chicago, Illinois). A p value < 0.05 was considered statistically significant for all comparisons.

3. Results

The cardiopulmonary parameters of the study patients are shown in Table 2. The patients with heart failure had significantly higher brain natriuretic peptide than the patients without heart failure. In the comparison of CPX parameters between the two groups, the patients with heart failure had significantly lower values of peak VO\(_2\) (16.5 ± 4.3 vs. 22.7 ± 4.3 mL/min/kg, \(p < 0.001\)), AT (12.5 ± 2.6 vs. 15.4 ± 3.1 mL/min/kg, \(p < 0.001\)), and \(\Delta\text{VO}_2/\Delta\text{WR}\) (9.1 ± 2.0 vs. 10.4 ± 1.4 mL/min/W, \(p = 0.002\)), and a significantly higher value of VE-VCO\(_2\) slope (34.6 ± 5.8 vs. 29.8 ± 4.2, \(p < 0.001\)).

Figure 2 shows the PWTT at rest, AT, and peak exercise in the study patients. When analyzed in the whole study population, PWTT was significantly shortened from rest to AT (204.6 ± 33.6 vs. 169.5 ± 31.4 msec, \(p < 0.001\)), and from AT to peak (169.5 ±
Table 1. Clinical characteristics of the study patients

| Characteristics                        | All Patients (n = 89) | Patients with HF (n = 38) | Patients without HF (n = 51) | p value |
|----------------------------------------|-----------------------|--------------------------|-----------------------------|---------|
| Male/Female                            | 45/44                 | 18/20                    | 27/24                       | 0.380   |
| Age (years)                            | 53.3 ± 21.9           | 59.8 ± 21.1              | 48.4 ± 21.4                 | 0.014   |
| Height (cm)                            | 160.2 ± 8.3           | 159.1 ± 7.9              | 161.1 ± 8.6                 | 0.460   |
| Weight (kg)                            | 59.9 ± 11.6           | 59.8 ± 11.8              | 60.0 ± 11.7                 | 0.909   |
| BMI (kg/m²)                            | 23.2 ± 3.6            | 23.6 ± 4.1               | 23.0 ± 3.2                  | 0.774   |
| **Etiology**                           |                       |                          |                             |         |
| Valvular disease                       | 28 (31.5)             | 8 (21.1)                 | 20 (39.2)                   | 0.105   |
| Congenital heart disease               | 25 (28.1)             | 7 (18.4)                 | 18 (35.3)                   | 0.098   |
| Coronary artery disease                | 19 (21.3)             | 12 (31.6)                | 7 (13.7)                    | 0.066   |
| Idiopathic dilated cardiomyopathy      | 6 (6.7)               | 6 (15.8)                 | 0                           | 0.005   |
| Arrhythmia                             | 5 (5.6)               | 0                        | 5 (9.8)                     | 0.069   |
| Other cardiac disease                  | 6 (6.7)               | 5 (13.2)                 | 1 (2.0)                     | 0.080   |
| **Complication**                       |                       |                          |                             |         |
| Hypertension                           | 44 (49.4)             | 23 (60.5)                | 21 (41.2)                   | 0.088   |
| Hyperlipidemia                         | 30 (33.7)             | 16 (42.1)                | 14 (27.5)                   | 0.177   |
| Diabetes                               | 25 (28.1)             | 16 (42.1)                | 9 (17.6)                    | 0.017   |
| Smokers                                | 22 (24.7)             | 13 (34.2)                | 9 (17.6)                    | 0.087   |
| Chronic kidney disease                 | 9 (10.1)              | 8 (21.1)                 | 1 (2.0)                     | 0.004   |
| Creatinine                             | 0.81 ± 0.25           | 0.90 ± 0.31              | 0.73 ± 0.15                 | 0.006   |
| Non-HDL cholesterol                    | 130.3 ± 36.2          | 130.5 ± 36.1             | 130.0 ± 37.1                | 0.412   |
| **Rhythm**                             |                       |                          |                             |         |
| Sinus                                  | 84 (94.4)             | 34 (89.5)                | 50 (98.0)                   | 0.159   |
| Atrial fibrillation                    | 2 (2.2)               | 2 (5.3)                  | 0                           | 0.180   |
| Pacing                                 | 3 (3.4)               | 2 (5.3)                  | 1 (2.0)                     | 0.573   |
| **Medication**                         |                       |                          |                             |         |
| β-blockers                             | 36 (40.4)             | 26 (68.4)                | 10 (19.6)                   | <0.001  |
| ACEI/ARB                               | 41 (46.1)             | 25 (65.8)                | 16 (31.4)                   | 0.001   |
| Diuretics                              | 30 (33.7)             | 22 (57.9)                | 8 (15.7)                    | <0.001  |
| Ca-channel blockers                    | 23 (25.8)             | 16 (42.1)                | 7 (13.7)                    | 0.003   |

Data are presented as the mean ± S.D. or No. (%) of patients unless otherwise indicated. HF, Heart failure; ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker.

Table 2. Cardiopulmonary parameters of the study patients

| Characteristics                  | All Patients (n = 89) | Patients with HF (n = 38) | Patients without HF (n = 51) | p value |
|----------------------------------|----------------------|--------------------------|-----------------------------|---------|
| **At rest**                      |                      |                          |                             |         |
| BNP (pg/mL)                      | 96.0 ± 132.8         | 145.0 ± 178.2            | 57.4 ± 59.1                 | 0.006   |
| LVEF (%)                         | 62.3 ± 10.5          | 59.9 ± 10.6              | 64.1 ± 10.2                 | 0.074   |
| LVDD (mm)                        | 46.6 ± 7.0           | 47.8 ± 6.4               | 45.8 ± 7.3                  | 0.176   |
| LVDD (mm)                        | 31.0 ± 7.1           | 32.6 ± 7.3               | 30.0 ± 6.8                  | 0.103   |
| Heart rate (beats/min)           | 75.5 ± 13.0          | 74.9 ± 15.1              | 75.9 ± 11.4                 | 0.723   |
| Systolic blood pressure (mmHg)   | 133.9 ± 24.7         | 138.8 ± 30.0             | 130.3 ± 19.4                | 0.107   |
| Diastolic blood pressure (mmHg)  | 76.0 ± 12.9          | 73.8 ± 12.7              | 77.7 ± 12.9                 | 0.150   |
| **At Peak Exercise**             |                      |                          |                             |         |
| Work rate (W)                    | 86.0 ± 32.2          | 69.8 ± 26.4              | 98.0 ± 31.0                 | <0.001  |
| Heart rate (beats/min)           | 135.6 ± 27.0         | 123.4 ± 27.1             | 144.6 ± 23.2                | <0.001  |
| Systolic blood pressure (mmHg)   | 181.2 ± 33.8         | 170.2 ± 34.4             | 189.3 ± 31.3                | 0.008   |
| Diastolic blood pressure (mmHg)  | 88.8 ± 16.4          | 83.7 ± 16.2              | 92.6 ± 15.7                 | 0.011   |
| R                                | 1.14 ± 0.13          | 1.11 ± 0.14              | 1.15 ± 0.12                 | 0.126   |
| Peak VO₂ (mL/min/kg)             | 20.0 ± 5.3           | 16.5 ± 4.3               | 22.7 ± 4.3                  | <0.001  |
| Peak VO₂ (%)                     | 78.2 ± 19.3          | 64.7 ± 14.6              | 88.3 ± 15.9                 | <0.001  |
| **VE-VCO₂ slope**                | 31.8 ± 5.4           | 34.6 ± 5.8               | 29.8 ± 4.2                  | <0.001  |
| AT (mL/min/kg)                   | 14.2 ± 3.2           | 12.5 ± 2.6               | 15.4 ± 3.1                  | <0.001  |
| ∆VO₂/∆WR (mL/min/W)              | 9.8 ± 1.8            | 9.1 ± 2.0                | 10.4 ± 1.4                  | 0.002   |
| **PWTT**                         |                      |                          |                             |         |
| Rest (ms)                        | 204.6 ± 33.6         | 202.9 ± 37.4             | 205.8 ± 30.8                | 0.687   |
| AT (ms)                          | 169.5 ± 31.4         | 171.7 ± 34.4             | 167.7 ± 29.0                | 0.570   |
| Peak (ms)                        | 145.6 ± 26.4         | 152.7 ± 27.1             | 140.4 ± 24.8                | 0.031   |
| Shortening of PWTT (%)           | 28.3 ± 10.1          | 23.8 ± 11.2              | 31.6 ± 7.8                  | <0.001  |

Data are presented as the mean ± S.D. or No. (%) of patients unless otherwise indicated. BNP, brain natriuretic peptide; LVDD, left ventricular diastolic dimension; LVDDs, left ventricular systolic dimension; LVEF, left ventricular ejection fraction; R, gas exchange ratio; VO₂, O₂ uptake; VE, minute ventilation; VCO₂, CO₂ output; AT, anaerobic threshold.
There were no significant differences in PWTT at rest between patients with and without heart failure in the present study. However, PWTT at peak exercise (145.6 ± 26.4 msec, p < 0.001). There were no significant differences in PWTT at rest or in AT between the patients with and without heart failure. The patients with heart failure, however, had significantly higher PWTT at peak exercise (152.7 ± 27.1 msec vs. 140.4 ± 24.8 msec, p = 0.031). The degree to which PWTT was shortened from rest to peak exercise was significantly lower in the patients with heart failure than in the patients without heart failure (23.8 ± 11.2 vs. 31.6 ± 7.8%, p < 0.001).

Figure 3 shows the correlations between the CPX indices and the shortening of the PWTT from rest to peak exercise in the patients with heart failure. The shortening of PWTT showed significant positive correlations with the peak VO₂, AT, and % increase in systolic blood pressure (r = 0.56, p < 0.001) and AT (r = 0.40, p = 0.016), and a negative correlation with the VE-VCO₂ slope (r = –0.42, p < 0.010). The shortening of PWTT showed a significant positive correlation with the % increase in systolic blood pressure (r = 0.75, p < 0.001).

4. Discussion

The PWTT was significantly shortened as the exercise intensity increased in the cardiac patients enrolled in this study. The patients with heart failure had significantly higher PWTT at peak exercise than the patients without heart failure. The shortening of PWTT from rest to peak exercise showed positive correlations with the peak VO₂, AT, and % increase in systolic blood pressure, and a negative correction with the VE-VCO₂ slope, indicating a lesser degree of shortening of PWTT in patients with lower exercise capacity and/or lower cardiopulmonary function during exercise.

4.1. Parameters obtained from CPX

The peak VO₂ generally reflects the maximal cardiac output during exercise. The peak VO₂ has been used as the main parameter of exercise capacity. The AT represents the highest level of VO₂ that a subject can perform without developing sustained lactic acidosis. The lower AT in cardiac patients signifies that the exercise-induced lactic acidosis occurs at a lower intensity of exercise (11,12). The ΔVO₂/ΔWR is mainly determined by the rate of the increase in cardiac output during incremental exercise. In normal subjects, the ΔVO₂/ΔWR is approximately 10 mL/min/W, and a lower ΔVO₂/ΔWR implies impaired response of cardiac output during exercise (13). The steeper VE-VCO₂ slope in heart failure patients mainly reflects high V/Q mismatch caused by reduced pulmonary blood flow (14). In the present study we found that the shortening of PWTT during exercise was lower in subjects with more advanced cardiopulmonary dysfunction, as reflected in a lower peak VO₂, lower AT, lower ΔVO₂/ΔWR, and higher VE-VCO₂ slope.

4.2. Mechanisms of the shortening of PWTT during exercise

The oxygen demand in skeletal muscle during exercise becomes higher with increasing exercise intensity. In response, the blood pressure, heart rate, and cardiac output rise to meet the increased oxygen demand in skeletal muscle. PWTT, the time of the pulse wave from the heart to the periphery, can therefore be expected to shorten in step with the increasing cardiac output as the exercise intensity increases.

There was no significant difference in PWTT at rest between patients with and without heart failure in the present study. However, PWTT at peak exercise
was significantly higher, and the degree of shortening of PWTT during exercise was significantly lower, in the heart failure patients. The shortening of PWTT during exercise was positively correlated with the increase in systolic blood pressure during exercise. Therefore, we assume that the lesser degree of PWTT shortening in the heart failure patients was caused by the limited increase in cardiac output during exercise, as systolic blood pressure partly reflects cardiac output. An impaired increase in cardiac output during exercise can be attributed to factors such as the appearance of myocardial ischemia or a worsening of valvular disease. Increased afterload resulting from excessive activity of the sympathetic nervous system or impaired production of the nitric oxide due to the vascular endothelial dysfunction in cardiac patients must also impair cardiac contractility, thereby influencing cardiac output during exercise.

To our knowledge, the present study is the first report which evaluated the change of PWTT during exercise and its relation with the parameters reflecting cardiopulmonary function during exercise. Standard noninvasive technologies estimating cardiac output have major limitations with regard to the applicability during routine clinical care (15). Very recently, Sano et al. (16) found that the change in PWTT predicts fluid responsiveness in mechanically ventilated anesthetized dogs given a fluid challenge. Suzuki et al. (17) also reported the usefulness of estimating cardiac output by PWTT at resting condition in patients after cardiovascular surgeries. Based on the findings of the recent reports and our study, monitoring of PWTT during exercise testing would provide noninvasive, and continuous estimate of cardiac output during exercise.

4.3. Limitations

PWTT during the whole period from rest to peak exercise could not be obtained in 13.6% of the patients investigated in this study. The PWTT values were missing most often near the point of peak exercise, probably as consequence of noise in the electrocardiogram caused by body movement or failure of the adhesive used to attach the oxygen saturation monitor to the earlobe. In the present study, 2 patients with atrial fibrillation and 3 patients with a pacemaker were included. Although the PWTT could be clearly recorded in these subjects, there is the possibility that the PWTT measurement might be influenced by the presence of atrial fibrillation or pacemakers. The small number of patients in the study precluded any subgroup analysis to consider parameters such as heart

Figure 3. Peak O$_2$ uptake (VO$_2$) (panel A), slope of the increase in ventilation versus the increase in CO$_2$ output (VE-VCO$_2$ slope) (panel B), anaerobic threshold (AT) (panel C), and % increase in systolic blood pressure (SBP) during exercise (panel D) plotted against the shortening of the pulse wave transit time (PWTT) in the patients with heart failure.
failure with reduced or preserved EF or the cardiac disease etiology. The patients with heart failure were more frequently prescribed medications that may have influenced the circulatory response, such as antihypertensive drugs and beta-blockers. The effects of these medications might be the reason for the higher exercise PWTT in the heart failure group compared to the non-heart failure group. Therefore, the consideration to choose a research design that can exclude the effects of these medications would have been desirable.

4.4. Future directions

Monitoring of PWTT during exercise testing might be useful as a noninvasive estimate of cardiac output during exercise. Further study in a larger population of cardiac patients will be needed to establish the clinical significance of PWTT during exercise.

4.5. Conclusions

PWTT was shortened during exercise as the exercise intensity increased. In the patients with heart failure, the shortening of PWTT from rest to peak exercise was smaller in those with lower exercise capacity and those with higher VE-VCO₂ slope, an established index known to reflect the severity of heart failure.

Acknowledgements

We thank for the support and encouragement from Department of Clinical Laboratory, University of Tsukuba Hospital.

References

1. Wippermann CF, Schranz D, Huth RG. Evaluation of the pulse wave arrival time as a marker for blood pressure changes in critically ill infants and children. J Clin Monit. 1995; 11:324-328.
2. Ochiai R, Takeda J, Hosaka H, Sugo Y, Tanaka R, Soma T. The relationship between modified pulse wave transit time and cardiovascular changes in isoflurane anesthetized dogs. J Clin Monit Comput. 1999; 15:493-501.
3. Balady GJ, Arena R, Sietsema K, et al. Clinician’s guide to cardipulmonary exercise testing in adults: A scientific statement from the American Heart Association. Circulation. 2010; 122:191-225.
4. Mancini DM, Eisen H, Kussmaul M, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991; 83:778-786.
5. Koike A, Itoh H, Kato M, Sawada H, Aizawa T, Fu LT, Watanabe H. Prognostic power of ventilatory responses during submaximal exercise in patients with chronic heart disease. Chest. 2002; 121:1581-1588.
6. Chua TP, Ponikowski P, Harrington D, Anker SD, Webb-Peploe K, Clark AL, Poole-Wilson PA, Coats AJ. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997; 29:1585-1590.
7. Beaver WL, Wasserman K, Whipp BJ. On-line computer analysis and breath-by-breath graphical display of exercise function tests. J Appl Physiol. 1973; 34:128-132.
8. Sue DY, Hansen JE, Blais M, Wasserman K. Measurement and analysis of gas exchange during exercise using a programmable calculator. J Appl Physiol. 1980; 49:456-461.
9. Itoh H, Koike A, Taniguchi K, Marumo F. Severity and pathophysiology of heart failure on the basis of anaerobic threshold (AT) and related parameters. Jpn Circ J. 1989; 53:146-154.
10. Wasserman K. New concepts in assessing cardiovascular function. Circulation. 1988; 78:1060-1071.
11. Matsumura N, Nishijima H, Kojima S, Hashimoto F, Minami M, Yasuda H. Determination of anaerobic threshold for assessment of functional state in patients with chronic heart failure. Circulation. 1983; 68:360-367.
12. Koike A, Hiroe M, Adachi H, Yajima T, Nomami A, Ito H, Takamoto T, Taniguchi K, Marumo F. Anaerobic metabolism as an indicator of aerobic function during exercise in cardiac patients. J Am Coll Cardiol. 1992; 20:120-126.
13. Cohen-Solal A, Chahernaud JM, Gourgon R. Comparison of oxygen uptake during bicycle exercise in patients with chronic heart failure and in normal subjects. J Am Coll Cardiol. 1990; 16:80-85.
14. Metra M, Dei Cas L, Panina G, Vissoli O. Exercise hyperventilation in chronic congestive heart failure, and its relation to functional capacity and hemodynamics. Am J Cardiol. 1992; 70:622-628.
15. Saugel B, Ceconi M, Hajjar LA. Noninvasive Cardiac Output Monitoring in Cardiothoracic Surgery Patients: Available Methods and Future Directions. J Cardiothorac Vasc Anesth. 2019; 33:1742-1752.
16. Sano H, Fujiyama M, Wightman P, Cave NJ, Gieseg MA, Johnson CB, Chambers P. Investigation of percentage changes in pulse wave transit time induced by mini-fluid challenges to predict fluid responsiveness in ventilated dogs. J Vet Emerg Crit Care (San Antonio). 2019; 29:391-398.
17. Suzuki T, Suzuki Y, Okuda J, Minoshima R, Misonoo Y, Ueda T, Kato J, Nagata H, Yamada T, Morisaki H. Cardiac output and stroke volume variation measured by the pulse wave transit time method: a comparison with an arterial pressure-based cardiac output system. J Clin Monit Comput. 2019; 33:385-392.

Received October 24, 2019; Revised December 24, 2019; Accepted February 3, 2020

*Address correspondence to:
Dr. Akira Koike, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
E-mail: koike@md.tsukuba.ac.jp

Released online in J-STAGE as advance publication February 17, 2020.